Cargando…
CAR T Cell Therapy: A Game Changer in Cancer Treatment
The development of novel targeted therapies with acceptable safety profiles is critical to successful cancer outcomes with better survival rates. Immunotherapy offers promising opportunities with the potential to induce sustained remissions in patients with refractory disease. Recent dramatic clinic...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889848/ https://www.ncbi.nlm.nih.gov/pubmed/27298832 http://dx.doi.org/10.1155/2016/5474602 |
_version_ | 1782435023722381312 |
---|---|
author | Almåsbak, Hilde Aarvak, Tanja Vemuri, Mohan C. |
author_facet | Almåsbak, Hilde Aarvak, Tanja Vemuri, Mohan C. |
author_sort | Almåsbak, Hilde |
collection | PubMed |
description | The development of novel targeted therapies with acceptable safety profiles is critical to successful cancer outcomes with better survival rates. Immunotherapy offers promising opportunities with the potential to induce sustained remissions in patients with refractory disease. Recent dramatic clinical responses in trials with gene modified T cells expressing chimeric antigen receptors (CARs) in B-cell malignancies have generated great enthusiasm. This therapy might pave the way for a potential paradigm shift in the way we treat refractory or relapsed cancers. CARs are genetically engineered receptors that combine the specific binding domains from a tumor targeting antibody with T cell signaling domains to allow specifically targeted antibody redirected T cell activation. Despite current successes in hematological cancers, we are only in the beginning of exploring the powerful potential of CAR redirected T cells in the control and elimination of resistant, metastatic, or recurrent nonhematological cancers. This review discusses the application of the CAR T cell therapy, its challenges, and strategies for successful clinical and commercial translation. |
format | Online Article Text |
id | pubmed-4889848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48898482016-06-13 CAR T Cell Therapy: A Game Changer in Cancer Treatment Almåsbak, Hilde Aarvak, Tanja Vemuri, Mohan C. J Immunol Res Review Article The development of novel targeted therapies with acceptable safety profiles is critical to successful cancer outcomes with better survival rates. Immunotherapy offers promising opportunities with the potential to induce sustained remissions in patients with refractory disease. Recent dramatic clinical responses in trials with gene modified T cells expressing chimeric antigen receptors (CARs) in B-cell malignancies have generated great enthusiasm. This therapy might pave the way for a potential paradigm shift in the way we treat refractory or relapsed cancers. CARs are genetically engineered receptors that combine the specific binding domains from a tumor targeting antibody with T cell signaling domains to allow specifically targeted antibody redirected T cell activation. Despite current successes in hematological cancers, we are only in the beginning of exploring the powerful potential of CAR redirected T cells in the control and elimination of resistant, metastatic, or recurrent nonhematological cancers. This review discusses the application of the CAR T cell therapy, its challenges, and strategies for successful clinical and commercial translation. Hindawi Publishing Corporation 2016 2016-05-19 /pmc/articles/PMC4889848/ /pubmed/27298832 http://dx.doi.org/10.1155/2016/5474602 Text en Copyright © 2016 Hilde Almåsbak et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Almåsbak, Hilde Aarvak, Tanja Vemuri, Mohan C. CAR T Cell Therapy: A Game Changer in Cancer Treatment |
title | CAR T Cell Therapy: A Game Changer in Cancer Treatment |
title_full | CAR T Cell Therapy: A Game Changer in Cancer Treatment |
title_fullStr | CAR T Cell Therapy: A Game Changer in Cancer Treatment |
title_full_unstemmed | CAR T Cell Therapy: A Game Changer in Cancer Treatment |
title_short | CAR T Cell Therapy: A Game Changer in Cancer Treatment |
title_sort | car t cell therapy: a game changer in cancer treatment |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889848/ https://www.ncbi.nlm.nih.gov/pubmed/27298832 http://dx.doi.org/10.1155/2016/5474602 |
work_keys_str_mv | AT almasbakhilde cartcelltherapyagamechangerincancertreatment AT aarvaktanja cartcelltherapyagamechangerincancertreatment AT vemurimohanc cartcelltherapyagamechangerincancertreatment |